Max Robotics — Global Service Robot Directory + US Certification

About

Atsushi Tsunoda is a prominent gynecologic oncologist whose work has significantly advanced the surgical management of early-stage cervical cancer. His research centers on developing and validating less invasive, fertility-sparing treatments that prioritize patient quality of life without compromising oncologic safety. Tsunoda is best known for his leadership of the 23 Concerv prospective trial, a landmark study that evaluated conservative surgery—specifically, simple hysterectomy or cone biopsy with pelvic lymph node dissection—for low-risk, early-stage cervical cancer. This work, published in 2019 and accruing 15 citations, provided critical evidence that less radical surgery can achieve excellent outcomes, challenging long-standing treatment paradigms and offering women a chance to preserve fertility. Beyond this trial, Tsunoda’s contributions include refining surgical techniques and establishing risk stratification criteria to identify ideal candidates for conservative approaches. His research has been instrumental in shifting clinical practice toward more personalized, less morbid care. For students and researchers, Tsunoda exemplifies how rigorous prospective trials can transform surgical oncology, demonstrating that innovation in treatment can be both safe and life-altering for patients.